Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
02/23/2023 | 98.02% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
11/14/2022 | 98.02% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
08/15/2022 | 197.03% | HC Wainwright & Co. | $12 → $9 | Maintains | Buy |
08/12/2022 | 65.02% | Sidoti & Co. | → $5 | Downgrades | Buy → Neutral |
05/16/2022 | 296.04% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
11/12/2021 | 395.05% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
03/29/2021 | — | Maxim Group | Downgrades | Buy → Hold | |
03/26/2021 | 428.05% | HC Wainwright & Co. | $30 → $16 | Maintains | Buy |
12/15/2020 | 890.1% | HC Wainwright & Co. | $29 → $30 | Maintains | Buy |
11/17/2020 | 857.1% | HC Wainwright & Co. | $33 → $29 | Maintains | Buy |
08/14/2020 | 989.11% | HC Wainwright & Co. | $35 → $33 | Maintains | Buy |
05/20/2020 | 890.1% | Maxim Group | → $30 | Upgrades | Hold → Buy |
05/18/2020 | 1055.12% | HC Wainwright & Co. | $20 → $35 | Reiterates | → Buy |
03/03/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
02/24/2020 | 32.01% | HC Wainwright & Co. | $2 → $4 | Maintains | Buy |
04/09/2019 | -33.99% | Maxim Group | → $2 | Initiates Coverage On | → Buy |
03/11/2019 | -33.99% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
What is the target price for Co-Diagnostics (CODX)?
The latest price target for Co-Diagnostics (NASDAQ: CODX) was reported by HC Wainwright & Co. on February 23, 2023. The analyst firm set a price target for $6.00 expecting CODX to rise to within 12 months (a possible 98.02% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Co-Diagnostics (CODX)?
The latest analyst rating for Co-Diagnostics (NASDAQ: CODX) was provided by HC Wainwright & Co., and Co-Diagnostics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Co-Diagnostics (CODX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Co-Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Co-Diagnostics was filed on February 23, 2023 so you should expect the next rating to be made available sometime around February 23, 2024.
Is the Analyst Rating Co-Diagnostics (CODX) correct?
While ratings are subjective and will change, the latest Co-Diagnostics (CODX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Co-Diagnostics (CODX) is trading at is $3.03, which is within the analyst's predicted range.